Acerus Pharmaceuticals (TSX:ASP) Short-Term Debt & Capital Lease Obligation : C$0.03 Mil (As of Sep. 2022)

View and export this data going back to 2009. Start your Free Trial

What is Acerus Pharmaceuticals Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Acerus Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was C$0.03 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Acerus Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was C$61.50 Mil.

Acerus Pharmaceuticals Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Acerus Pharmaceuticals's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acerus Pharmaceuticals Short-Term Debt & Capital Lease Obligation Chart

Acerus Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

1.31

0.13

2.14

2.78

Acerus Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															2.72	2.78	7.19	7.30	0.03

Acerus Pharmaceuticals Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Acerus Pharmaceuticals Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Acerus Pharmaceuticals's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Acerus Pharmaceuticals (TSX:ASP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acerus Pharmaceuticals Corp (TSX:ASP) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

7025 Langer Drive, Suite 205, Mississauga, ON, CAN, L5N 0E8

Website

https://www.aceruspharma.com

Acerus Pharmaceuticals Corp is a specialty pharmaceutical company focused on the development, manufacture, marketing and distribution of branded products that improve patient experience, with a primary focus on the field of men's health. Its foundational product includes NATESTO, a testosterone therapy based on nasal gel technology. The company commercializes its products via its salesforce in the United States and Canada, and through a global network of licensed distributors in other territories.

Executives

Norma Beauchamp	Director
Stephen Robert Gregory	Director
Edward Joseph Gudaitis	Director, Senior Officer